Incyte

Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Endpoints
Thu, 07/23/20 - 11:06 am
ruxolitinib
Novartis
Incyte
graft vs host disease
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
Tue, 05/5/20 - 11:52 pm
Incyte
earnings
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Mon, 04/27/20 - 09:43 am
Novartis
Incyte
AACR
lung cancer
MET inhibitors
capmatinib
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Wed, 04/22/20 - 10:45 pm
Novartis
Incyte
Jakafi
clinical trials
COVID-19
cytokine storm
graft vs host disease
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Mon, 04/20/20 - 10:58 am
Incyte
Pemazyre
pemigatinib
bile duct cancer
cholangiocarcinoma
FDA
Incyte, Novartis launch drug study to treat coronavirus complication
Marketwatch
Sat, 04/18/20 - 11:22 pm
Incyte
Novartis
cytokine storm
COVID-19
clinical trials
Jakafi
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
Fri, 04/3/20 - 12:02 am
cancer
COVID-19
Incyte
Jakafi
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Tue, 03/17/20 - 11:59 am
Eli Lilly
Incyte
breakthrough therapy
FDA
baricitinib
alopecia areata
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Fierce Biotech
Wed, 02/19/20 - 09:58 am
Incyte
ruxolitinib
clinical trials
atopic dermatitis
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Fierce Pharma
Thu, 02/13/20 - 11:28 pm
Incyte
Jakafi
pemigatinib
Incyte Earnings, Revenue Beat in Q4
Yahoo/Investing.com
Thu, 02/13/20 - 11:00 am
Incyte
earnings
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Thu, 02/13/20 - 12:12 am
Eli Lilly
Incyte
olumiant
eczema
clinical trials
atopic dermatitis
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Tue, 02/11/20 - 10:28 am
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Incyte's skin disease drug meets main goal in late-stage study
Yahoo/Reuters
Tue, 01/28/20 - 12:00 pm
Incyte
clinical trials
atopic dermatitis
ruxolitinib
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Incyte
MorphoSys
lymphoma
tafasitamab
Incyte stock slammed after study fails to hit goal
Marketwatch
Thu, 01/2/20 - 11:44 pm
Incyte
clinical trials
itacitinib
graft vs host disease
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Tue, 12/3/19 - 09:47 am
Incyte
Jakafi
innovation
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
Fri, 11/29/19 - 02:24 pm
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
BioSpace
Sat, 11/2/19 - 07:55 pm
earnings
Pfizer
Merck
Amgen
Incyte
JNJ
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Yahoo/Zacks.com
Sat, 10/19/19 - 01:28 pm
Incyte
earnings

Pages